Psychotherapeutics: Antidepressants, Antipsychotics, Antianxiety Drugs, World Market

    Published: January 1, 2007 | Price: $995.00 – $7,000.00

    The market for psychotherapeutics drugs is about to change dramatically -- and serious pharmaceutical market watchers will want to be prepared. Kaloramaā€™s Psychotherapeutics: Antidepressants, Antipsychotics, Antianxiety Drugs: World Market is the most exhaustive guide available to this booming market and the direction it is headed in the next four years. Psychotherapeutics treat conditions classified as abnormal behavior, thoughts and feelings that persist for a determined amount of time causing distress or emotional/physical impairment. Depression, anxiety, psychosis, ADHD and nicotine and...
    World Market for Prescription Orthopedic Drugs, The

    Published: October 1, 2006 | Price: $995.00 – $7,000.00

    The orthopedic drug market is a highly competitive market and, in some areas, the competitive environment is being shaped by increasing levels of generic competition. Several large pharmaceutical companies compete in the orthopedic drug market, including Abbott, Eli Lilly, GlaxoSmithKline, Merck, Novartis, and Pfizer among others, and several other suppliers, such as Serono, NovoNordisk, Amgen, and Genentech are developing or offering products in more niche market areas. For the purposes of this study, the world market for orthopedic drugs has...
    Pharmaceutical Outsourcing Opportunities Post-Launch – Contract Manufacturing and Contract Sales and Marketing, 2nd Edition

    Published: September 1, 2006 | Price: $3,900.00 – $7,800.00

    This report is focused on two expanding pharmaceutical outsourcing markets, contract manufacturing and contract sales and marketing. Both markets represent excellent post launch outsourcing opportunities for companies competing in this fast growing pharmaceutical outsourcing sector. The report contains vital market statistics on three main segments of pharmaceutical contract manufacturing: Biopharmaceutical manufacturing, including monoclonal antibodies (MAbs), complex proteins, peptides, nucleotides, DNA vaccines, and gene therapy. Primary pharmaceutical manufacturing, including non-sterile and sterile active pharmaceutical ingredients (APIs), custom chemicals, certain specialized manufacturing...
    World Market for Prescription Gastrointestinal Drugs, The

    Published: July 1, 2006 | Price: $995.00 – $7,000.00

    This report provides and in-depth analysis of the market for prescription drugs used in the treatment of gastrointestinal (GI) disorders, such as nausea and vomiting, heartburn, gastro-esophageal reflux disease (GERD), ulcer, cancers of the GI tract (colorectal, esophageal, and gastric), Crohnā€™s disease, ulcerative colitis, irritable bowel syndrome (IBS), diverticular disease, constipation, celiac disease, short bowel syndrome, diarrhea, intestinal obstruction, and digestive enzyme disorders. For each major segment, the analysis provides an overview of the diseases including epidemiology, a detailed description...
    Advances in Ophthalmology – Markets in the Treatment of Eye Disorders and Corrective Vision

    Published: July 1, 2006 | Price: $2,995.00 – $7,800.00

    Ophthalmology is entering one of the most remarkable phases in recent history of this industry; new technologies and treatment modalities for both visual acuity and major eye diseases may dramatically change the composition and competitive dynamics of this market. As RK and LASIK changed the market a few years ago, even newer competitive technologies are just now emerging. From the advent of photodynamic therapy and new drug delivery techniques to revolutionary surgical approaches to refractive vision correction, ophthalmology is poised...
    Critical Care Pharmaceutical Markets – A Strategic Analysis

    Published: June 1, 2006 | Price: $995.00 – $5,990.00

    This report focuses on the specific needs and market applications of the critical care pharmaceuticals market, the options presented by the market, the factors associated with strategic market development, and prospects for the future. The major indications for critical care are discussed as well as the range of pharmaceutical products used in the critical care environment. The strategic market characteristics of the critical care pharmaceuticals market are also discussed. The trends ā€”- cost-containment programs, restricted formulary acceptance, clinical pharmacy, and...
    The World Market for Prescription Generic Drugs, 5th Edition

    Published: April 1, 2006 | Price: $2,500.00 – $7,000.00

    The landscape of generic companies is changing: their relative might in the industry is increasing and the product lines their offering are growing in depth and breadth. Strong growth in the sector has come not only from more aggressive tactics and better acceptance in the clinical and consumer population, but by the loss of patent protection in the past few years of some huge-name drugs, including Prozac, Zocor, Prilosec, Prevacid, Sporanox, Evista, Flovent, Claritin, Allegra, Diflucan, Zofran, Zoloft, and Pravachol....
    The Worldwide Market for Prescription Dermatological Drugs, 5th Edition

    Published: February 1, 2006 | Price: $1,995.00 – $7,800.00

    This report provides the reader with a comprehensive analysis of the domestic and international markets involving pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatologic Drugs is the fifth time Kalorama Information has comprehensively studied the dermatology markets. As is the case with each new edition, Kalorama completely re-evaluated the market from the ground up, and in addition to the usual primary interviewing of industry participants, clinicians, and regulators, we also conducted scores of...
    Worldwide Market for Pediatric Drugs, 2nd Edition, The

    Published: November 1, 2005 | Price: $3,500.00 – $7,000.00

    Although, the next 15-20 years will shift a majority of the population into the elderly population group, children will continue to remain the bulk of the dependent population worldwide with 9 in every 10 people falling into a pediatric age range in the less developed regions of Africa, Asia and Latin America. Therefore, the treatment of conditions and diseases affecting pediatrics and the healthy growth of children are vital to providing a solid foundation for healthy adults in the future....
    The World Market for Neurotherapeutic Drugs

    Published: September 1, 2005 | Price: $3,500.00 – $7,000.00

    Management of both acute and chronic neurologic diseases can be challenging for both the patient and the health care provider. Many neurologic disorders involve progressive deterioration in physical and mental capabilities, which can be devastating to the patient and the patientā€™s family. In many respects, neurotherapeutics represent the largest as-yet untapped market in medicine. This Kalorama Information report focuses on several key product segments of neurotherapeutic treatment: Alzheimerā€™s Disease and Other Dementias Brain and Neurologic Cancers Brain Trauma and Stroke...
    The World Market for Anti-Infectives, Volume III – Antivirals

    Published: June 1, 2005 | Price: $2,500.00 – $5,000.00

    This volume of Kalorama Informationā€™s World Market for Anti-Infectives series focuses on three general product segments of antiviral treatment: Nucleoside Analogs Protease Inhibitors Other Misc. Antivirals The report covers both currently marketed and late stage development antiviral products in detail. For each segment, the report provides an An overview Description of products on the market Description of products in development Market estimates and forecasts through 2009 Market segmentation by infection type Market segmentation by geographic region Market share of leading...
    The World Market for Anti-Infectives, Volume II – Antibacterials

    Published: May 1, 2005 | Price: $2,500.00 – $5,000.00

    For the past 60 years, antibiotic drugs have changed bacterial infections from the life-threatening scourges they once were into eminently treatable conditions. However, the effectiveness of many antibiotics is waning dramatically, as more and more types of bacteria become resistant to traditional agents. As a result, pharmaceutical companies are taking a second look at the antibiotic market, after more than two decades of relative complacency. In addition to the scientific and technical challenges of new antibiotic development, there are significant...
    The Worldwide Market for Prescription Cardiovascular Drugs

    Published: May 1, 2005 | Price: $3,500.00 – $7,000.00

    The worldwide market for prescription cardiovascular drugs encompasses a wide variety of products that treat the many facets of cardiovascular disease. The field of cardiology is currently experiencing a busy and dynamic period. As a result, the range of therapeutic options available to physicians has expanded significantly in the past few years and the development pipeline promises even more weapons soon. The sheer size and diversity of the current market and the potential of new products make this therapeutic category...
    World Market for Anti-Infectives, Volume I: Antifungals, The

    Published: April 1, 2005 | Price: $2,500.00 – $5,000.00

    In the past 100 years, there has been a steady increase in the incidence of serious secondary systemic fungal infections. One of the factors aiding the spread of fungal disease has been the widespread use of broad-spectrum antibiotics, which eliminate or decrease the non-pathogenic bacterial populations that normally compete with fungi. Another has been the vast increase in populations with with compromised immune response (caused by AIDS or by the action of immunosuppressant drugs or cancer chemotherapy agents). In addition...
    Schizophrenia Therapeutics: A Market Briefing

    Published: April 1, 2005 | Price: $995.00 – $1,990.00

    Schizophrenia is a life long affliction. There is no permanent cure for this illness. However, numerous drugs have made the effective management of the disease a reality. This briefing examines both corrent and emerging therapeutic approaches for the management of schizophrenia. It provides an analysis of the current and future markets for these agents, including forecasts to 2009 segmented by geographic region and by type of drug and likely market scenarios for new agents not yet available. The briefing discusses...